The Potential Effects of Light Irradiance in Glaucoma and Photobiomodulation Therapy (2024)

As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsem*nt of, or agreement with, the contents by NLM or the National Institutes of Health.
Learn more: PMC Disclaimer | PMC Copyright Notice

The Potential Effects of Light Irradiance in Glaucoma and Photobiomodulation Therapy (1)

Link to Publisher's site

Bioengineering (Basel). 2023 Feb; 10(2): 223.

Published online 2023 Feb 7. doi:10.3390/bioengineering10020223

PMCID: PMC9952036

PMID: 36829717

Sang-Hyun Ahn,1, Jung-Soo Suh,1, Gah-Hyun Lim,1,2,3,* and Tae-Jin Kim1,2,3,*

Hiroshi Ohguro, Academic Editor

Author information Article notes Copyright and License information PMC Disclaimer

Associated Data

Data Availability Statement

Abstract

Human vision is mediated by the retina, one of the most critical tissues in the central nervous system. Glaucoma is a complex retinal disease attributed to environmental, genetic, and stochastic factors, all of which contribute to its pathogenesis. Historically, glaucoma had been thought of primarily as a disease of the elderly; however, it is now becoming more problematic as the incidence rate increases among young individuals. In recent years, excessive light exposure has been suggested as contributing to the rise in glaucoma among the younger generation. Blue light induces mitochondrial apoptosis in retinal ganglion cells, causing optic damage; red light increases cytochrome c oxidase activity in the electron transport system, reducing inflammation and increasing antioxidant reactions to promote cell regeneration. In conclusion, the minimization of blue light exposure and the general application of red light treatment strategies are anticipated to show synergistic effects with existing treatments for retinal disease and glaucoma and should be considered a necessary prospect for the future. This review introduces the recent studies that support the relationship between light exposure and the onset of glaucoma and discusses new treatments, such as photobiomodulation therapy.

Keywords: blue light, glaucoma, oxidative stress, photobiomodulation, retinal ganglion cell

1. Introduction

Given the development of modern technology and the changes in the lifestyle of modern society, reliance on electronic displays has been recognized as the main cause of the rise in the incidence of eye diseases. In particular, glaucoma, an age-related disease, has become a serious problem because its incidence rate continues to rise even in young people. Glaucoma is a neurodegenerative disease characterized by progressive and functional deterioration of the optic nerve head (ONH) and retinal nerve fiber layer (RNFL) [1]. Once the light reaches the retina, it is converted into electrical signals by photoreceptors, and the optic nerve transmits it to the brain [2]. Glaucoma causes the field of view to become narrower due to a reduction in the optic nerve cells, and as it worsens, it leads to blindness. By 2013, 64.3 million cases of glaucoma had been diagnosed worldwide. This number had increased to 76.0 million by 2020, and is projected to increase to 111.8 million by 2040 [3].

There are three main causes of glaucoma: age, ischemia, and structural factors. An increase in age increases the incidence of glaucoma due to cellular senescence and functional cell deterioration [4]. In addition, when the ocular perfusion pressure decreases due to hypotension, which is a representative symptom of ischemia, or ischemia occurs due to high blood pressure or diabetes, oxygen and nutrients are not smoothly supplied to the optic nerve, and damage to the optic nerve may occur. A leading cause of the structural factors is an increase in intraocular pressure (IOP), defined as the ratio of the discharged aqueous humor to the aqueous humor produced by the ciliary body [4,5]. Eventually, when the intraocular water discharge is suppressed due to the trabecular meshwork or damage to the iris, IOP increases. Depending on the cause (trabecular meshwork or iris), it is called primary open-angle glaucoma (POAG) or primary angle-closure glaucoma (PACG). However, glaucoma can occur even when the IOP is within the statistically normal range (10–21 mm Hg), which is classified as normal-tension glaucoma (NTG). NTG may be caused by secondary glaucoma [5], which, in turn, is caused by other eye diseases, such as neovascularization and uveitis, or differences in individual sensitivity to IOP. In particular, it has been reported that the incidence of glaucoma in patients with high myopia was much higher than in those without myopia due to structural abnormalities of the eyeball [6,7]. High myopia is a disease in which the axial length of the eyeball grows excessively, and the image is formed in front of the retina. Individuals with high myopia are structurally more susceptible to glaucoma than those without [8]. This supports the results of some epidemiological investigations that state that an increase in the number of highly myopic patients in the young and old due to modern lifestyle habits can lead to an increase in the incidence of glaucoma [6,9].

Glaucoma is not only increasing in incidence rate but also decreasing in the age of onset. According to an investigation by the Korean Health Insurance Review and Assessment Service, the number of glaucoma patients aged between 10–29 years continued to increase between 2013–2018. It has emerged as one of the main eye diseases threatening the quality of life [9]. The increasing prevalence of glaucoma in young people has several causes. Specifically, the increase in metabolic syndrome in young people due to the changes in eating habits in modern society has impacted the incidence of glaucoma [10,11]. Metabolic syndrome refers to a person suffering from three or more metabolic disorders, such as high blood pressure, diabetes, and high blood cholesterol. Lack of exercise, which is effective in preventing certain types of degenerative vision loss, has also contributed to the increase in the number of glaucoma patients [12,13]. In addition, excessive use of digital media (computers, mobile phones, etc.) increases sleep disturbance and insomnia, increases IOP due to incorrect posture or cortisol production disorders, and oxygen deficiency due to sleep apnea directly damages the optic nerve, leading to glaucoma [14]. Generations with high digital media consumption suffer from dry eye syndrome daily, which has a significant effect on the increase in intraocular pressure. Also, rubbing the eye and angiogenesis caused by dry eye syndrome directly damage the eye, causing glaucoma [15,16,17]. Among them, an increase in the number of patients with high myopia and increased exposure to blue light, effects of the modern lifestyle that depend on electronic displays, are drawing attention as the main causes [18,19,20,21,22]. Therefore, in this review, we focus on light exposure as the cause of glaucoma and summarize research trends and related content on glaucoma and light irradiance. In addition, we introduce the clinical effect of photobiomodulation (PBM) treatment, which has been of interest in recent years and provide essential data for comprehensively understanding the pathological mechanism of glaucoma according to the wavelength of light and for establishing a glaucoma treatment strategy.

2. Human Eye Anatomy and Physiology

The normal human eye is a sphere that measures 24 mm in diameter and has unique anatomical and physiological functions [23]. There are three layers of membranes in the eye: the outer, the middle, and the inner layers, apart from other interior contents [24] (Figure 1A). The outer layer constitutes the cornea and the sclera; the middle layer, the choroid, the ciliary membrane, and the iris; and the inner layer, the retina, the lens, and the vitreous and aqueous humors. The retina is the tissue that lines the inner surface of the eye. The cells of the neural retina are composed of several parallel layers [25,26,27]. Several types of cells are found in the retina, such as photoreceptors, astrocytes, Müller cells, retinal ganglion cells, glial cells, amacrine cells, bipolar cells, horizontal cells, and retinal pigment epithelial (RPE) cells (Figure 1B). The nuclei of photo-receptors are located in the outer nuclear layer, and the outer segments are located proximally from the nuclei close to the RPE cells. The nuclei of Müller cells, bipolar cells, and amacrine cells are located in the inner nuclear layer of the retina. Bipolar cells and horizontal cells connect with photo-receptors, and bipolar cells and amacrine cells synapse with ganglion cells. The nuclei of retinal ganglion cells are in the ganglion layer, and their axons are in the nerve fiber layer. Müller cells also form synapses with dendrites of neurons and axons of the nerve fiber layer [25]. A part of the central nervous system, the retina converts light energy into electrical signals and transmits them to the brain via the optic nerve. In addition, the retina receives oxygen and nutrients through the retinal blood vessels and the choroidal capillaries in contact with Müller cells. RPE cells are an epithelial cell monolayer between photo-receptors and a layer of capillaries adjacent to the innermost layer of the choroid [26]. RPE cells consist of approximately 3.5 million epithelial cells arranged in a hexagonal pattern and relatively evenly distributed throughout the retina. Numerous pigments (melanin and lipofuscin) are present in the cytoplasm of RPE cells. Important functions of RPE cells include maintenance of photoreceptor function, adhesion to the retina, production of growth factors necessary for surrounding tissues, and wound healing upon injury [26,28,29,30,31]. In addition, it plays an important role in blood-retinal barrier function and metabolite excretion [32]. Glaucoma can develop due to aging, ischemia, or structural factors; these lead to optic disc cupping, a specific phenomenon of damage to the retinal nerve fiber layer (stratum opticum). The optic nerve disc concavity is a phenomenon in which the neuroretinal rim decreases in size due to an increase in the ratio of the optic cup to the optic disc and results in the deformation of the lamina cribrosa. As a result of the deformation of the lamina cribrosa, gradual damage to the axons and cell bodies of the retinal ganglion cells occurs. Therefore, when biochemical alterations in the optic nerve cause a decrease in blood flow and an increase in oxidative stress, excitatory toxicity, autophagy, apoptosis, and necroptosis-associated signal transduction processes occur. This damages the retinal ganglion cells and causes vision loss. A study by Weinreb and Khaw (2004) showed that a tomographic image of the retina could be observed in three dimensions using near-infrared rays through optical coherence tomography. In this study, the retinal nerve fiber layer and the ganglion cell inner plexiform layer (GCIPL) were examined in normal and glaucomatous eyes. GCIPL comparison was carried out to confirm the death of the retinal ganglion cells [1].

The Potential Effects of Light Irradiance in Glaucoma and Photobiomodulation Therapy (2)

Structure of the eye and retina. (A) Structure of the eyeball consists of the cornea, lens, iris, macula, retina, and optic nerve that transmits visual information from the retina to the brain. (B) Cellular unit of the retinal layer. This figure was created using PowerPoint & BioRender (Available online: http://biorender.com (accessed on 9 April 2020)).

3. The Effects of Blue Light on the Eyes

Light is necessary for the retina to convert light energy into electrical signals and transmit them to the brain via the optic nerve, even though it is not always beneficial to the retina. Several mitochondria are present in the nodes of Ranvier of retinal ganglion cells in the retina, which take up a significant amount of energy. Osborne et al. (2006) confirmed that blue light adversely affects the mitochondria of retinal ganglion cells. Moreover, there is evidence that the mitochondrial electron transport chain-related enzymes flavin and cytochrome C oxidase (CCO) are damaged by blue light, resulting in the generation of photochemical effects and reactive oxygen species (ROS) (Figure 2) [33]. ROS are normally regulated by antioxidants, but in eyes deformed by ischemia or myopia, blue light leads to excessive production of ROS and mitochondrial DNA damage. Ultimately, this results in the loss of the visual field owing to a cascade of events leading to cell death [22]. A previous study has shown that when exposed to blue light under ischemic conditions, the retina produces relatively low levels of ATP, the retinal ganglion cells are damaged, and mitochondrial energy metabolism is inhibited [34].

The Potential Effects of Light Irradiance in Glaucoma and Photobiomodulation Therapy (3)

Schematic illustration of the proposed mechanism by which blue light causes glaucoma. This figure was created using PowerPoint & BioRender (Available online: http://biorender.com (accessed on 9 April 2020).

Despite the limitations associated with its visual assessment, it is possible to determine the degree of aging in cells by measuring the amount of galactosidase that accumulates with the progression of cellular aging and by detecting ROS inside the cells. Kernt et al. (2012), in an experiment using human retinal epithelial cells stained for detecting beta-galactosidase activity, showed that blue light-induced cell senescence and that the degree of intracellular ROS decreased when the blue light was filtered [19]. In another study, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to confirm that the survival rate of retinal epithelial cells exposed to blue light was lower than that of cells exposed to darkness, suggesting that blue light induced a decrease in mitochondrial activity and lowered energy levels, resulting in the induction of apoptosis [18]. There are two general mechanisms by which programmed cell death is induced: apoptosis and necroptosis. Apoptosis is induced when the apoptosis-inducing factor (AIF), which exists in the spaces between the mitochondrial membranes of retinal epithelial cells, splits into two molecules, gets activated, and enters the nucleus of the cell. In contrast, necroptosis is programmed necrosis within the cell, in which receptor-interacting protein kinase 1 (RIP1) and receptor-interacting protein kinase 3 (RIP3) form a complex and perform their functions [35]. In addition to activating AIF in retinal cells, blue light also stimulates RIP1 and RIP3 activation in retinal ganglion cells [36]. Osborne et al. (2017) demonstrated that while AIF was expressed intact in retinal cells cultured under dark conditions, it was expressed as two fragments under blue light conditions. Furthermore, retinal ganglion cells exposed to blue light reportedly showed a lower survival rate than those exposed to dark illumination, and the survival rate increased significantly when the expression of RIP1 and RIP3 proteins was inhibited through small interfering RNA (siRNA) technology [34]. It is evident that blue light activates both apoptosis and apoptotic necrosis in retinal cells, which may contribute to the onset or exacerbation of glaucoma.

4. Red Light and PBM Therapy

PBM is used, in its simplest form, for the biomodulation of photons of light. Among the various light wavelength ranges, red light has been observed to show a positive therapeutic effect [37,38,39]. In the past, lasers gained attention as a means of scanning red light; however, continuously scanning light at a wavelength of 620 nm could damage the eyes [39]. However, in recent years, LEDs have completely compensated for these disadvantages, and near-infrared rays with a wavelength range of approximately 780–940 nm have also become available [38]. PBM therapy was initially named low-level laser (light) therapy (LLLT), a biological treatment using a laser or LED, but was changed to PBM due to ambiguity in the standard of the low–level [37]. According to Calabrese et al. (2013) [40], no biological change is induced when red light intensity is low, and the ‘hormesis effect’ is observed above a certain intensity [41]. It has also been reported that when the light intensity exceeded the above-mentioned level, the positive effect decreased and tissue damage occurred [42].

Another study confirmed that treatment with a red light of appropriate intensity reduced oxidative stress and inflammation in living organisms, helping in the regeneration of cells and rapid tissue recovery [43,44]. Active studies on the influences of PBM therapy show positive effects on peripheral nerve tissue repair [45,46,47,48,49,50]. Peripheral nerve lesions have caused significant impairment in individuals’ daily lives due to the lack of effective treatments for recovery. At the cellular level, PBM therapy is associated with efficient nerve regeneration by improving nutritional status, reducing inflammation, and promoting the secretion of nerve factors [51,52]. In addition, changes in TNF-α, Il-1β, and GAP-43 levels suggest that PBM therapy in nerve injury is associated with the reduction of inflammatory cytokines and promotion of nerve regeneration [53,54]. Better wound healing in ischemic organs was also confirmed due to increased secretion of antiapoptotic factors [55,56]. Therefore, neurological PBM therapy provides faster and higher-quality recovery for the morphological healing of regenerating peripheral nerves and reduces inflammation and painful sensitivity [57,58]. This review was inspired by the positive effects of PBM therapy on these nerve cells and investigated its effects on the damage caused by light, especially glaucoma, which is directly related to the destruction of the optic nerve.

5. Mechanism of Eye Recovery through PBM Therapy

The therapeutic efficacy of red light is considered to be due to an increase in the activity of CCO, one of the complexes constituting the mitochondrial electron transport system [59,60]. CCO is an enzyme that catalyzes the oxidation reaction of cytochrome C, reducing oxygen molecules to water. It consists of two heme structures, cytochrome α and cytochrome α3, and two central copper structures, CuA and CuB [59]. According to a previous study by Mason et al. [61], a total of four electrons, transferred one by one through CCO, were delivered to the catalytic site (heme iron) with a binuclear copper center (cytochrome α3/CuB) through reduced cytochrome C, CuA, and cytochrome α. One molecule of oxygen is reduced at the catalytic site to form two molecules of water, and it has been reported that ATP synthesis is activated by the proton gradient [42,62]. Activation of CCO is greater than that of nitric oxide (nitric oxide: a gas that has a stronger affinity for CCO than oxygen and is structurally similar to oxygen), which functions as a competitive endogenous mediator of CCO when oxygen is enriched. It is induced by increasing the binding force to CCO [63,64]. However, Cleeter et al. (1994) confirmed that cytochrome C oxidase in the state of potential glaucoma has a low oxygen concentration, which decreases its activity and inhibits energy production [65]. In contrast, Brown and Cooper [66] found that red light plays a role in increasing the activity of CCO by photodissociating nitric oxide from cytochrome C oxidase. The PBM treatment is more effective since damaged cells and tissues contain more nitric oxide than healthy cells [42]. It has also been reported that when red light increases the activity of CCO, energy levels increase as ATP production improves and antioxidant production, such as of vitamins C and E, is stimulated, resulting in a decrease in ROS levels for a long period.

The increase in IOP transforms the eye into a state susceptible to secondary damage [67]. To prevent and treat glaucoma, IOP increase, and aging, the two fundamental causes, must be suppressed. As a result, PBM therapy is emerging as an effective means of enhancing mitochondrial function in retinal ganglion cells [43,44]. Osborne et al. (2017) artificially increased IOP in an experiment using rats. The control group was reared under dark conditions, and the experimental group was reared under red light (16.5 watts/m, 3000 lux, 625–635 nm) for a week. The results confirmed that the retinal epithelial cells of rats treated with red light had far less damage from IOP than those of the rats in the control group. Another study that compared and analyzed the effects of blue versus red light reported that in the presence of each of the lights of optimal energy value (blue light at 470 nm, 12.08 W/m2; red light at 630 nm, 6.5 W/m2), the survival rate of cells exposed to red light was higher than that of those exposed to blue light. The results of this study indicate that red light enhances mitochondrial function and increases ATP synthesis [20]. Further studies also proved that while blue light increases ROS, red light enhances mitochondrial function by regulating ROS. Furthermore, red light alleviates the damage caused by ischemia and reduces glial fibrillary acidic protein (GFAP), associated with the stress response. Therefore, blue light is damaging to retinal cells, while red light is beneficial [20].

6. Advantages of PBM Therapy

The most common treatment for glaucoma is the prescription of eye drops. In addition to the hypotensive drugs, modern devices that inject drugs, locally and systemically, to lower IOP are also used. However, low patient compliance and unstable adherence are the major disadvantages of eye drop therapy. Regarding surgery, although traditional trabeculectomy remains the standard method of treatment, the latest trend is focused on improving the risk/benefit ratio of minimally invasive glaucoma surgery. This is because PBM is a safer and more efficient technique for lowering IOP than standard surgery. The red light (630–1000 nm) used for PBM therapy is a long-wavelength light that can pass through thick tissues compared to other wavelengths (Figure 3). Thus, it may be expected that retinal ganglion cells may now be treated non-surgically, without the need to cut the eye, through the therapeutic effects of red light. In addition, the fact that drug therapies were administered directly to the eyes increased the overall risk of side effects. However, red light is absorbed as it passes through the retina to induce therapeutic effects, so the possibility of side effects is relatively low [68].

The Potential Effects of Light Irradiance in Glaucoma and Photobiomodulation Therapy (4)

Illustration showing the proposed mechanism by which red light may have a beneficial effect on glaucoma. This figure was created using PowerPoint & BioRender (Available online: http://biorender.com (accessed on 9 April 2020).

7. Conclusions

The eye is one of the few major organs constantly exposed to the external environment. Various wavelengths of light from the outside environment continuously enter the retina and eventually affect the eye’s health. Based on the results of previous studies, it can be concluded that the increase in the incidence of glaucoma and the decrease in the age of onset may be attributed to the relationship between myopia and blue light and that the use of red light in promoting cell regeneration and reducing ROS can be a valid treatment strategy for this condition. Blue light, a short-wavelength visible light, induces apoptosis by disrupting the balance between mitochondrial antioxidative and ROS production processes in retinal ganglion cells; both these processes play an important role in visual processing (Figure 2). Owing to the deformation of the eyeball, a myopic eye is particularly susceptible to secondary damage caused by blue light. The most basic and effective measure to prevent such eye damage is to avoid excessive exposure to blue light. Basically, since glaucoma is caused by an increase in IOP or damage to the optic nerve, it is necessary to wear sunglasses when outdoors to prevent strong light from entering the eyeball and properly adjust the brightness of digital screens [69,70,71]. These habits are basic and routine methods recommended to be maintained even after glaucoma surgery [72]. However, treatment after the onset of glaucoma is still limited.

In contrast, PBM therapy, which is emerging as a new treatment for glaucoma, induces the inhibition of nitric oxide in the electron transport system and promotes an increase in the activity of CCO, reduces oxidative stress and inflammatory reactions in the eye, and increases energy production in the cells (Figure 3). Furthermore, since red light has a high tissue penetration rate and is a non-surgical treatment, it has fewer side effects and is less burdensome for the retina. However, the current treatment options for glaucoma are limited to direct injection of drugs into the eye as eye drops or laser ablation of the trabecular meshwork to reduce IOP. There is a need for additional epidemiological and clinical studies on both the harmful and the therapeutic effects of light on eye diseases. Currently, research is underway to develop eye treatment technologies and devices using the enhancing effect of red light [73], as well as to develop special lenses that would convert UV rays into green or red light [74]. Many positive effects are anticipated through the synergistic effects of the combination of PBM therapy, which enhances the resilience of the optic nerve, along with existing treatments. The general application of PBM treatment strategies for retinal diseases and glaucoma should be considered a necessary prospect for the future.

Funding Statement

This research was supported by the PNU-RENovation (2021–2022). This study was also supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) [2022R1A4A5031503 and 2022M3E5F2017929].

Author Contributions

Conceptualization, S.-H.A. and T.-J.K.; methodology, J.-S.S.; validation, T.-J.K.; formal analysis, S.-H.A. and T.-J.K.; investigation, S.-H.A. and T.-J.K.; writing-original draft preparation, S.-H.A., J.-S.S. and T.-J.K.; writing-review and editing, S.-H.A., G.-H.L. and T.-J.K.; supervision, G.-H.L. and T.-J.K.; project administration, G.-H.L. and T.-J.K.; funding acquisition, G.-H.L. and T.-J.K. All authors have read and agreed to the published version of the manuscript.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no competing interests. The authors have no financial relationships to photo modulation therapy.

Footnotes

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

References

1. Weinreb R.N., Tee Khaw P. Primary Open-Angle Glaucoma. Lancet. 2004;363:1711–1720. doi:10.1016/S0140-6736(04)16257-0. [PubMed] [CrossRef] [Google Scholar]

2. Laha B., Stafford B.K., Huberman A.D. Regenerating Optic Pathways from the Eye to the Brain. Science. 2017;356:1031–1034. doi:10.1126/science.aal5060. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

3. Tham Y.C., Li X., Wong T.Y., Quigley H.A., Aung T., Cheng C.Y. Global Prevalence of Glaucoma and Projections of Glaucoma Burden through 2040: A Systematic Review and Meta-Analysis. Ophthalmology. 2014;121:2081–2090. doi:10.1016/j.ophtha.2014.05.013. [PubMed] [CrossRef] [Google Scholar]

4. Rudnicka A.R., Mt-Isa S., Owen C.G., Cook D.G., Ashby D. Variations in Primary Open-Angle Glaucoma Prevalence by Age, Gender, and Race: A Bayesian Meta-Analysis. Investig. Ophthalmol. Vis. Sci. 2006;47:4254–4261. doi:10.1167/iovs.06-0299. [PubMed] [CrossRef] [Google Scholar]

5. Foster P.J., Buhrmann R., Quigley H.A., Johnson G.J. The Definition and Classification of Glaucoma in Prevalence Surveys. Br. J. Ophthalmol. 2002;86:238–242. doi:10.1136/bjo.86.2.238. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

6. Marcus M.W., De Vries M.M., Junoy Montolio F.G., Jansonius N.M. Myopia as a Risk Factor for Open-Angle Glaucoma: A Systematic Review and Meta-Analysis. Ophthalmology. 2011;118:1989–1994.e2. doi:10.1016/j.ophtha.2011.03.012. [PubMed] [CrossRef] [Google Scholar]

7. Chen S.J., Lu P., Zhang W.F., Lu J.H. High Myopia as a Risk Factor in Primary Open Angle Glaucoma. Int. J. Ophthalmol. 2012;5:750–753. doi:10.3980/j.issn.2222-3959.2012.06.18. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

8. Kolb H., Ralph N., Eduardo F. Webvision: The Organization of the Retina and Visual System. University of Utah Health Sciences Center; Salt Lake City, UT, USA: 1995. [PubMed] [Google Scholar]

9. Hong K.-H., Kim S.-J. A Study of Medical Costs According to the Number of Myopic Patients in Korea. Korean J. Vis. Sci. 2017;19:149–158. doi:10.17337/JMBI.2017.19.2.149. [CrossRef] [Google Scholar]

10. Jeong Y.C., Hwang Y.H. Etiology and Features of Eyes with Rubeosis Iridis among Korean Patients: A Population-Based Single Center Study. PLoS ONE. 2016;11:4–11. doi:10.1371/journal.pone.0160662. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

11. Kim H.A., Han K., Lee Y.A., Choi J.A., Park Y.M. Differential Association of Metabolic Risk Factors with Open Angle Glaucoma According to Obesity in a Korean Population. Sci. Rep. 2016;6:38283. doi:10.1038/srep38283. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

12. Abokyi S., Mensah S.N., Otchere H., Akoto Y.O., Ntodie M. Differential Effect of Maximal Incremental Treadmill Exercise on Tear Secretion and Tear Film Stability in Athletes and Non-Athletes. Exp. Eye Res. 2022;214:108865. doi:10.1016/j.exer.2021.108865. [PubMed] [CrossRef] [Google Scholar]

13. Makin R.D., Argyle D., Hirahara S., Nagasaka Y., Zhang M., Yan Z., Kerur N., Ambati J., Gelfand B.D. Voluntary Exercise Suppresses Choroidal Neovascularization in Mice. Retin. Cell Biol. 2020;61:52. doi:10.1167/iovs.61.5.52. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

14. Sun C., Yang H., Hu Y., Qu Y., Hu Y., Sun Y., Ying Z., Song H. Association of Sleep Behaviour and Pattern with the Risk of Glaucoma: A Prospective Cohort Study in the UK Biobank. BMJ Open. 2022;12:e063676. doi:10.1136/bmjopen-2022-063676. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

15. Lee S.M., Jin S.W. Efficacy of Preservative-Free Latanoprost in Normal-Tension Glaucoma with Mild to Moderate Dry Eye. J. Korean Ophthalmol. Soc. 2020;61:639–644. doi:10.3341/jkos.2020.61.6.639. [CrossRef] [Google Scholar]

16. Rossi G.C.M., Tinelli C., Pasinetti G.M., Milano G., Bianchi P.E. Dry Eye Syndrome-Related Quality of Life in Glaucoma Patients. Eur. J. Ophthalmol. 2009;19:572–579. doi:10.1177/112067210901900409. [PubMed] [CrossRef] [Google Scholar]

17. Savastano A., Savastano M.C., Carlomusto L., Savastano S. Bilateral Glaucomatous Optic Neuropathy Caused by Eye Rubbing. Case Rep. Ophthalmol. 2015;6:279–283. doi:10.1159/000439163. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

18. Godley B.F., Shamsi F.A., Liang F.Q., Jarrett S.G., Davies S., Boulton M. Blue Light Induces Mitochondrial DNA Damage and Free Radical Production in Epithelial Cells. J. Biol. Chem. 2005;280:21061–21066. doi:10.1074/jbc.M502194200. [PubMed] [CrossRef] [Google Scholar]

19. Kernt M., Walch A., Neubauer A.S., Hirneiss C., Haritoglou Md C., Ulbig M.W., Kampik A. Filtering Blue Light Reduces Light-Induced Oxidative Stress, Senescence and Accumulation of Extracellular Matrix Proteins in Human Retinal Pigment Epithelium Cells. Clin. Exp. Ophthalmol. 2012;40:e87–e97. doi:10.1111/j.1442-9071.2011.02620.x. [PubMed] [CrossRef] [Google Scholar]

20. Núñez-Álvarez C., Osborne N.N. Blue Light Exacerbates and Red Light Counteracts Negative Insults to Retinal Ganglion Cells in Situ and R28 Cells in Vitro. Neurochem. Int. 2019;125:187–196. doi:10.1016/j.neuint.2019.02.018. [PubMed] [CrossRef] [Google Scholar]

21. Osborne N.N., Lascaratos G., Bron A.J., Chidlow G., Wood J.P.M. A Hypothesis to Suggest That Light Is a Risk Factor in Glaucoma and the Mitochondrial Optic Neuropathies. Br. J. Ophthalmol. 2006;90:237–241. doi:10.1136/bjo.2005.082230. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

22. Osborne N.N. Mitochondria: Their Role in Ganglion Cell Death and Survival in Primary Open Angle Glaucoma. Exp. Eye Res. 2010;90:750–757. doi:10.1016/j.exer.2010.03.008. [PubMed] [CrossRef] [Google Scholar]

23. Kels B.D., Grzybowski A., Grant-Kels J.M. Human Ocular Anatomy. Clin. Dermatol. 2015;33:140–146. doi:10.1016/j.clindermatol.2014.10.006. [PubMed] [CrossRef] [Google Scholar]

24. Chinnery H.R., McMenamin P.G., Dando S.J. Macrophage Physiology in the Eye. Pflugers Arch. Eur. J. Physiol. 2017;469:501–515. doi:10.1007/s00424-017-1947-5. [PubMed] [CrossRef] [Google Scholar]

25. Miller N.R., Walsh F.B., Hoyt W.F. Walsh and Hoyt’s Clinical Neuro-Ophthalmology. Volume 1. Lippincott Williams & Wilkins; Philadelphia, PA, USA: 2005. [Google Scholar]

26. Schubert H.D. Structure and Function of the Neural Retina. Ophthalmology. 2009;2:771–774. [Google Scholar]

27. Masland R.H. The Functional Architecture of the Retina. Sci. Am. 1986;255:102–111. doi:10.1038/scientificamerican1286-102. [PubMed] [CrossRef] [Google Scholar]

28. Young R.W. The Renewal of Rod and Cone Outer Segments in the Rhesus Monkey. J. Cell Biol. 1971;49:303–318. doi:10.1083/jcb.49.2.303. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

29. Foulds W.S. Do We Need a Retinal Pigment Epithelium (or Choroid) for the Maintenance of Retinal Apposition? Br. J. Ophthalmol. 1985;69:237–239. doi:10.1136/bjo.69.4.237. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

30. Grierson I., Hiscott P., Hogg P., Robey H., Mazure A., Larkin G. Development, Repair and Regeneration of the Retinal Pigment Epithelium. Eye. 1994;8:255–262. doi:10.1038/eye.1994.54. [PubMed] [CrossRef] [Google Scholar]

31. Reh T.A., Levine E.M. Multipotential Stem Cells and Progenitors in the Vertebrate Retina. J. Neurobiol. 1998;36:206–220. doi:10.1002/(SICI)1097-4695(199808)36:2<206::AID-NEU8>3.0.CO;2-5. [PubMed] [CrossRef] [Google Scholar]

32. Willermain F., Scifo L., Weber C., Caspers L., Perret J., Delporte C. Potential Interplay between Hyperosmolarity and Inflammation on Retinal Pigmented Epithelium in Pathogenesis of Diabetic Retinopathy. Int. J. Mol. Sci. 2018;19:1056. doi:10.3390/ijms19041056. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

33. Tao J.X., Zhou W.C., Zhu X.G. Mitochondria as Potential Targets and Initiators of the Blue Light Hazard to the Retina. Oxid. Med. Cell. Longev. 2019;2019:6435364. doi:10.1155/2019/6435364. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

34. del Olmo-Aguado S., Núñez-Álvarez C., Osborne N.N. Blue Light Action on Mitochondria Leads to Cell Death by Necroptosis. Neurochem. Res. 2016;41:2324–2335. doi:10.1007/s11064-016-1946-5. [PubMed] [CrossRef] [Google Scholar]

35. Fink S.L., Cookson B.T. Apoptosis, Pyroptosis, and Necrosis: Mechanistic Description of Dead and Dying Eukaryotic Cells. Infect. Immun. 2005;73:1907–1916. doi:10.1128/IAI.73.4.1907-1916.2005. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

36. Lane N. POWER GAMES. Nat. Publ. Gr. 2006;443:901–903. doi:10.1038/443901a. [PubMed] [CrossRef] [Google Scholar]

37. Anders J.J., Lanzafame R.J., Arany P.R. Low-Level Light/Laser Therapy versus Photobiomodulation Therapy. Photomed. Laser Surg. 2015;33:183–184. doi:10.1089/pho.2015.9848. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

38. Kim W.S., Glen Calderhead R. Is Light-Emitting Diode Phototherapy (LED-LLLT) Really Effective? Laser Ther. 2011;20:205–215. doi:10.5978/islsm.20.205. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

39. Hosseini-Zijoud S.M. The Importance of Coherency. Photomed. Laser Surg. 2005;23:431–434. [PubMed] [Google Scholar]

40. Calabrese E.J., Iavicoli I., Calabrese V. Hormesis: Its Impact on Medicine and Health. Hum. Exp. Toxicol. 2013;32:120–152. doi:10.1177/0960327112455069. [PubMed] [CrossRef] [Google Scholar]

41. del Olmo-Aguado S., Núñez-Álvarez C., Osborne N.N. Red Light of the Visual Spectrum Attenuates Cell Death in Culture and Retinal Ganglion Cell Death in Situ. Acta Ophthalmol. 2016;94:e481–e491. doi:10.1111/aos.12996. [PubMed] [CrossRef] [Google Scholar]

42. Hamblin M.R. Mechanisms and Mitochondrial Redox Signaling in Photobiomodulation. Photochem. Photobiol. 2018;94:199–212. doi:10.1111/php.12864. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

43. Wong-Riley M.T.T., Liang H.L., Eells J.T., Chance B., Henry M.M., Buchmann E., Kane M., Whelan H.T. Photobiomodulation Directly Benefits Primary Neurons Functionally Inactivated by Toxins: Role of Cytochrome c Oxidase. J. Biol. Chem. 2005;280:4761–4771. doi:10.1074/jbc.M409650200. [PubMed] [CrossRef] [Google Scholar]

44. Liang H.L., Whelan H.T., Eells J.T., Meng H., Buchmann E., Lerch-Gaggl A., Wong-Riley M. Photobiomodulation Partially Rescues Visual Cortical Neurons from Cyanide-Induced Apoptosis. Neuroscience. 2006;139:639–649. doi:10.1016/j.neuroscience.2005.12.047. [PubMed] [CrossRef] [Google Scholar]

45. de Oliveira Gonçalves J.B., Buchaim D.V., de Souza Bueno C.R., Pomini K.T., Barraviera B., Júnior R.S.F., Andreo J.C., de Castro Rodrigues A., Cestari T.M., Buchaim R.L. Effects of Low-Level Laser Therapy on Autogenous Bone Graft Stabilized with a New Heterologous Fibrin Sealant. J. Photochem. Photobiol. B. 2016;162:663–668. doi:10.1016/j.jphotobiol.2016.07.023. [PubMed] [CrossRef] [Google Scholar]

46. Buchaim D.V., Andreo J.C., Ferreira Junior R.S., Barraviera B., Rodrigues A.d.C., Macedo M.d.C., Rosa Junior G.M., Shinohara A.L., Santos German I.J., Pomini K.T., et al. Efficacy of Laser Photobiomodulation on Morphological and Functional Repair of the Facial Nerve. Photomed. Laser Surg. 2017;35:442–449. doi:10.1089/pho.2016.4204. [PubMed] [CrossRef] [Google Scholar]

47. Rosso M.P.d.O., Rosa Júnior G.M., Buchaim D.V., German I.J.S., Pomini K.T., de Souza R.G., Pereira M., Favaretto Júnior I.A., Bueno C.R. de S.; Gonçalves, J.B. de O.; et al. Stimulation of Morphofunctional Repair of the Facial Nerve with Photobiomodulation, Using the End-to-Side Technique or a New Heterologous Fibrin Sealant. J. Photochem. Photobiol. B. 2017;175:20–28. doi:10.1016/j.jphotobiol.2017.08.023. [PubMed] [CrossRef] [Google Scholar]

48. Buchaim R.L., Andreo J.C., Barraviera B., Ferreira Junior R.S., Buchaim D.V., Rosa Junior G.M., de Oliveira A.L.R., de Castro Rodrigues A. Effect of Low-Level Laser Therapy (LLLT) on Peripheral Nerve Regeneration Using Fibrin Glue Derived from Snake Venom. Injury. 2015;46:655–660. doi:10.1016/j.injury.2015.01.031. [PubMed] [CrossRef] [Google Scholar]

49. de Vasconcellos L.M.R., Barbara M.A.M., Rovai E.d.S., de Oliveira França M., Ebrahim Z.F., de Vasconcellos L.G.O., Porto C.D., Cairo C.A.A. Titanium Scaffold Osteogenesis in Healthy and Osteoporotic Rats Is Improved by the Use of Low-Level Laser Therapy (GaAlAs) Lasers Med. Sci. 2016;31:899–905. doi:10.1007/s10103-016-1930-y. [PubMed] [CrossRef] [Google Scholar]

50. Buchaim D.V., Rodrigues A.d.C., Buchaim R.L., Barraviera B., Junior R.S.F., Junior G.M.R., Bueno C.R.D.S., Roque D.D., Dias D.V., Dare L.R., et al. The New Heterologous Fibrin Sealant in Combination with Low-Level Laser Therapy (LLLT) in the Repair of the Buccal Branch of the Facial Nerve. Lasers Med. Sci. 2016;31:965–972. doi:10.1007/s10103-016-1939-2. [PubMed] [CrossRef] [Google Scholar]

51. Yazdani S.O., Golestaneh A.F., Shafiee A., Hafizi M., Omrani H.-A.G., Soleimani M. Effects of Low Level Laser Therapy on Proliferation and Neurotrophic Factor Gene Expression of Human Schwann Cells in Vitro. J. Photochem. Photobiol. B. 2012;107:9–13. doi:10.1016/j.jphotobiol.2011.11.001. [PubMed] [CrossRef] [Google Scholar]

52. Hashmi J.T., Huang Y.-Y., Osmani B.Z., Sharma S.K., Naeser M.A., Hamblin M.R. Role of Low-Level Laser Therapy in Neurorehabilitation. PM&R. 2010;2:S292–S305. doi:10.1016/j.pmrj.2010.10.013. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

53. Gigo-Benato D., Geuna S., de Castro Rodrigues A., Tos P., Fornaro M., Boux E., Battiston B., Giacobini-Robecchi M.G. Low-Power Laser Biostimulation Enhances Nerve Repair after End-to-Side Neurorrhaphy: A Double-Blind Randomized Study in the Rat Median Nerve Model. Lasers Med. Sci. 2004;19:57–65. doi:10.1007/s10103-004-0300-3. [PubMed] [CrossRef] [Google Scholar]

54. Rochkind S., Drory V., Alon M., Nissan M., Ouaknine G.E. Laser Phototherapy (780 Nm), a New Modality in Treatment of Long-Term Incomplete Peripheral Nerve Injury: A Randomized Double-Blind Placebo-Controlled Study. Photomed. Laser Surg. 2007;25:436–442. doi:10.1089/pho.2007.2093. [PubMed] [CrossRef] [Google Scholar]

55. Wang C.-Z., Chen Y.-J., Wang Y.-H., Yeh M.-L., Huang M.-H., Ho M.-L., Liang J.-I., Chen C.-H. Low-Level Laser Irradiation Improves Functional Recovery and Nerve Regeneration in Sciatic Nerve Crush Rat Injury Model. PLoS ONE. 2014;9:e103348. doi:10.1371/journal.pone.0103348. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

56. Chen Y.-J., Wang Y.-H., Wang C.-Z., Ho M.-L., Kuo P.-L., Huang M.-H., Chen C.-H. Effect of Low Level Laser Therapy on Chronic Compression of the Dorsal Root Ganglion. PLoS ONE. 2014;9:e89894. doi:10.1371/journal.pone.0089894. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

57. Bang J., Kim H.Y., Lee H. Optogenetic and Chemogenetic Approaches for Studying Astrocytes and Gliotransmitters. Exp. Neurobiol. 2016;25:205–221. doi:10.5607/en.2016.25.5.205. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

58. Iyer S.M., Vesuna S., Ramakrishnan C., Huynh K., Young S., Berndt A., Lee S.Y., Gorini C.J., Deisseroth K., Delp S.L. Optogenetic and Chemogenetic Strategies for Sustained Inhibition of Pain. Sci. Rep. 2016;6:30570. doi:10.1038/srep30570. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

59. Begum R., Powner M.B., Hudson N., Hogg C., Jeffery G. Treatment with 670 Nm Light Up Regulates Cytochrome C Oxidase Expression and Reduces Inflammation in an Age-Related Macular Degeneration Model. PLoS ONE. 2013;8:1–11. doi:10.1371/journal.pone.0057828. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

60. Gkotsi D., Begum R., Salt T., Lascaratos G., Hogg C., Chau K.Y., Schapira A.H.V., Jeffery G. Recharging Mitochondrial Batteries in Old Eyes. Near Infra-Red Increases ATP. Exp. Eye Res. 2014;122:50–53. doi:10.1016/j.exer.2014.02.023. [PubMed] [CrossRef] [Google Scholar]

61. Mason M.G., Nicholls P., Wilson M.T., Cooper C.E. Nitric Oxide Inhibition of Respiration Involves Both Competitive (Heme) and Noncompetitive (Copper) Binding to Cytochrome c Oxidase. Proc. Natl. Acad. Sci. USA. 2006;103:708–713. doi:10.1073/pnas.0506562103. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

62. Taylor C.T., Moncada S. Nitric Oxide, Cytochrome c Oxidase, and the Cellular Response to Hypoxia. Arterioscler. Thromb. Vasc. Biol. 2010;30:643–647. doi:10.1161/ATVBAHA.108.181628. [PubMed] [CrossRef] [Google Scholar]

63. Moncada S. Adventures in Vascular Biology: A Tale of Two Mediators. Philos. Trans. R. Soc. B Biol. Sci. 2006;361:735–759. doi:10.1098/rstb.2005.1775. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

64. Schweizer M., Richter C. Nitric Oxide Potently and Reversibly Deenergizes Mitochondria at Low Oxygen Tension. Biochem. Biophys. Res. Commun. 1994;204:169–175. doi:10.1006/bbrc.1994.2441. [PubMed] [CrossRef] [Google Scholar]

65. Cleeter M.W.J., Cooper J.M., Darley-Usmar V.M., Moncada S., Schapira A.H.V. Reversible Inhibition of Cytochrome c Oxidase, the Terminal Enzyme of the Mitochondrial Respiratory Chain, by Nitric Oxide. Implications for Neurodegenerative Diseases. FEBS Lett. 1994;345:50–54. doi:10.1016/0014-5793(94)00424-2. [PubMed] [CrossRef] [Google Scholar]

66. Brown G.C., Cooper C.E. Nanomolar Concentrations of Nitric Oxide Reversibly Inhibit Synaptosomal Respiration by Competing with Oxygen at Cytochrome Oxidase. FEBS Lett. 1994;356:295–298. doi:10.1016/0014-5793(94)01290-3. [PubMed] [CrossRef] [Google Scholar]

67. Bonomi L., Marchini G., Marraffa M., Morbio R., Gandham S.B. The Relationship between IOP and Glaucoma in a Defined Population. Evid.-Based Eye Care. 2001;2:234–235. doi:10.1097/00132578-200110000-00024. [CrossRef] [Google Scholar]

68. Osborne N.N., Núñez-Álvarez C., del Olmo-Aguado S., Merrayo-Lloves J. Visual Light Effects on Mitochondria: The Potential Implications in Relation to Glaucoma. Mitochondrion. 2017;36:29–35. doi:10.1016/j.mito.2016.11.009. [PubMed] [CrossRef] [Google Scholar]

69. Terrie Y.C.B.T.-P.T. Glaucoma: Getting a Clear View: Early Detection and Treatment Are Key to Protecting Eyesight. Pharm. Times. 2015;81:54. [Google Scholar]

70. Kong G.Y.X., Van Bergen N.J., Trounce I.A., Crowston J.G. Mitochondrial Dysfunction and Glaucoma. J. Glaucoma. 2009;18:93–100. doi:10.1097/IJG.0b013e318181284f. [PubMed] [CrossRef] [Google Scholar]

71. Wolffsohn J.S., Cochrane A.L. Low Vision Perspectives on Glaucoma. Clin. Exp. Optom. 1998;81:280–289. doi:10.1111/j.1444-0938.1998.tb06748.x. [PubMed] [CrossRef] [Google Scholar]

72. Kyari F., Mohammed M.A. The Basics of Good Postoperative Care after Glaucoma Surgery. Community Eye Health J. 2016;429:29–31. [PMC free article] [PubMed] [Google Scholar]

73. Tedford C.E., Delapp S., Bradley S. Devices and Methods for Non-Invasive Multi-Wavelength Photobiomodulation for Ocular Treatments. US20160067086A1. U.S. Patent. 2016 March 10;

74. Li L., Sahi S.K., Peng M., Lee E.B., Ma L., Wojtowicz J.L., Malin J.H., Chen W. Luminescence-and Nanoparticle-Mediated Increase of Light Absorption by Photoreceptor Cells: Converting UV Light to Visible Light. Sci. Rep. 2016;6:20821. doi:10.1038/srep20821. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Articles from Bioengineering are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)

The Potential Effects of Light Irradiance in Glaucoma and Photobiomodulation Therapy (2024)

FAQs

What are the effects of photobiomodulation? ›

Laser and LED light induce a photobiomodulation (PBM) effect which is used to accelerate healing, as it increases cell viability by stimulating the mitochondrial and cell membrane photoreceptors synthesis of ATP.

Is red light therapy bad for glaucoma? ›

Based on the results of previous studies, it can be concluded that the increase in the incidence of glaucoma and the decrease in the age of onset may be attributed to the relationship between myopia and blue light and that the use of red light in promoting cell regeneration and reducing ROS can be a valid treatment ...

How does light affect glaucoma? ›

Halogen lights, like those used in car headlights, and fluorescent store lighting or fixtures can cause an uncomfortable glare for those with glaucoma, as well. A bright sunny day can cause not only discomfort due to a patient's sensitivity, but also create glare off surfaces such as sand, water, glass, or pavement.

What is the light treatment for glaucoma? ›

Laser Trabeculoplasty

A high-intensity beam of light is aimed through the lens. It triggers a chemical and biological change in the tissue of the trabecular meshwork, the region that is blocking the fluid's exit from the eye. The laser helps to improve drainage of fluid out of the eye and into the bloodstream.

Does photobiomodulation really work? ›

Over the last seventy years or so, many previous studies have shown that photobiomodulation, the use of red to near infrared light on body tissues, can improve central and peripheral neuronal function and survival in both health and in disease.

What are the bad things about red light therapy? ›

Potential side effects

There is a low risk of side effects from undergoing RLT. However, prolonged or high-intensity exposure outside of treatment guidelines may damage the skin. Products for use at home may also lead to misuse, causing burns, blisters or damage to unprotected eyes.

Does red light repair eyes? ›

Age-related macular degeneration is a leading cause of vision loss in older adults. Studies have shown that red light therapy can help slow the progression of AMD by promoting the growth and survival of retinal cells, reducing inflammation, and improving blood flow to the macula.

What type of light is best for glaucoma? ›

Ambient light levels with uniform illumination provide better vision quality. Softening shadows and glare are easier on the eye. Achieve this by installing overhead lighting with even light distribution, wall sconces with matte lenses or shades, and table or floor lamps placed in seating areas.

What makes glaucoma worse? ›

We know glaucoma is made worse by high pressure in the eye or a reduced flow of blood to the optic nerve, so anything we do that decreases eye pressure or blood pressure may help.

Does watching TV affect glaucoma? ›

Prolonged screen time and digital device use are not currently considered as a risk factor for glaucoma.

What is the life expectancy of glaucoma patients? ›

Upon diagnosis, patients with glaucoma have an average life expectancy of 9 to 13 years,2 and if the goal is to preserve visual function during their lifetime, then the optic nerve should be evaluated for glaucomatous damage at every visit.

Do sunglasses help glaucoma? ›

A study on low vision care highlights that every glaucoma patient needs sunglasses that can reduce the effects of glare and improve their visual contrast. However, the study cited that some people must also use prescription glasses that can correct presbyopia and other eye conditions related to glaucoma.

What is the newest treatment for glaucoma? ›

iDose TR treats glaucoma by automatically releasing the same type of medication used for decades in the most commonly prescribed eye drops. After 12 months of a clinical study, 81% of people were able to eliminate the burden of taking daily eye drops.

What is the best treatment for glaucoma in the world? ›

Micro-Invasive Glaucoma Surgery (MIGS) has become the preferred approach to glaucoma management for many eye care professionals and their patients with mild-to-moderate glaucoma.

Can I do red light therapy with my eyes closed? ›

Red light therapy is generally considered a safe and effective method for all skin types, but there are a few common sense caveats. Step one: close your eyes. “If you're keeping your eyes open, the light can cause damage,” says Bowe. Next, your red light device, nor your skin, should never be hot, or even warm.

How long does it take for photobiomodulation to work? ›

Most patients receive treatment five days a week, for two or more weeks (typically a total of 10-30 treatments). Some patients will need more than 10 treatments to get the best results. The number of sessions will be decided with your care team according to your clinical progress.

Who should not use photobiomodulation? ›

People who take medications that increase their skin or eye sensitivity should not use red light therapy. People who have a history of skin cancer or eye disease should speak with their doctor before using red light therapy.

What does red light therapy do for the body? ›

Red light therapy is thought to work by acting on the “power plant” in your body's cells called mitochondria. With more energy, other cells can do their work more efficiently, doing things like repairing skin, boosting new cell growth and enhancing skin rejuvenation.

Is photobiomodulation the same as red light therapy? ›

Photobiomodulation (PBM) therapy, also known as low-level light therapy and red-light therapy, involves shining red or near-infrared (NIR) light at wavelengths between 600 nm–1200 nm onto the head through an LED light.

References

Top Articles
Latest Posts
Article information

Author: Clemencia Bogisich Ret

Last Updated:

Views: 6028

Rating: 5 / 5 (80 voted)

Reviews: 87% of readers found this page helpful

Author information

Name: Clemencia Bogisich Ret

Birthday: 2001-07-17

Address: Suite 794 53887 Geri Spring, West Cristentown, KY 54855

Phone: +5934435460663

Job: Central Hospitality Director

Hobby: Yoga, Electronics, Rafting, Lockpicking, Inline skating, Puzzles, scrapbook

Introduction: My name is Clemencia Bogisich Ret, I am a super, outstanding, graceful, friendly, vast, comfortable, agreeable person who loves writing and wants to share my knowledge and understanding with you.